The goal of this clinical trial is to compare the pharmacokinetic profile of the single intravenous injection of the test product and reference product in healthy subjects and to evaluate the bio-equivalence and safety of these two injections in healthy subjects. The main questions it aims to answer are:
[Question 1] Is there significant difference in the pharmacokinetic profile between the Iron Sucrose Injection (100 mg/5 mL [calculated by iron]) manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd. and the Iron Sucrose Injection (trade name: Venofer®, 100 mg/5 mL [calculated by iron]) held by Vifor France? [Question 2] Is it safe for the healthy subjects to take the test product (100 mg/5 mL [calculated by iron]) manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd. and the reference product held by Vifor France? Participants will be randomly divided into group I and group II, with equal number of subjects in each group. Each subject will receive only one dose of either the test product or the reference product in each period (two-sequence crossover study).

Start Date22 Nov 2024

Sponsor / Collaborator

Sichuan Huiyu Pharmaceutical Co., Ltd.

[+2]

CTR20244071

/ Active, not recruitingNot Applicable

蔗糖铁注射液人体生物等效性研究

[Translation] Study on bioequivalence of iron sucrose injection in healthy volunteers

主要目的：本试验旨在研究健康受试者单次静脉注射四川汇宇制药股份有限公司研制、生产的蔗糖铁注射液（5 ml:100 mg铁和1.6 g蔗糖）在健康受试者体内的药代动力学特征；以Vifor France持证的蔗糖铁注射液（Venofer®，5 ml:100 mg铁）为参比制剂，比较两制剂中药动学参数的差异，评价两制剂的人体生物等效性。次要目的：评估受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Primary objective: This study aims to study the pharmacokinetic characteristics of a single intravenous injection of iron sucrose injection (5 ml: 100 mg iron and 1.6 g sucrose) developed and produced by Sichuan Huiyu Pharmaceutical Co., Ltd. in healthy subjects; using Vifor France's certified iron sucrose injection (Venofer®, 5 ml: 100 mg iron) as the reference preparation, compare the differences in pharmacokinetic parameters between the two preparations, and evaluate the human bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation and the reference preparation in healthy subjects.

Start Date18 Nov 2024

Sponsor / Collaborator

Sichuan Huiyu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Iron sucrose

100 Translational Medicine associated with Iron sucrose

100 Patents (Medical) associated with Iron sucrose

23,049

Literatures (Medical) associated with Iron sucrose

31 Dec 2025·Energy Sources Part A-Recovery Utilization and Environmental Effects

Characterization of anaerobic methanogenic process in the goethite dosed continuous reactors under different pH

Author: Gao, Hongwen ; Wang, Jin ; Yue, Zhengbo ; Ma, Ding

Although conductive materials (CM) gained increasing attention over the last decades to facilitate methane production, its influence on the whole process of anaerobic digestion was not clear yet, especially for the acidogenesis.The purpose of this study was to investigate the role of goethite on methane production and its effects on the volatile fatty acids (VFAs) in acidogenesis under different pH conditions.Results showed that the methane production and COD (COD) removal efficiency in continuous stirring tank reactors (CSTRs) were increased with the addition of goethite.The promotion effects of goethite were particularly significant under acidic conditions.Microbial community anal. indicated that Clostridium and Syntrophic bacteria were enriched in goethite-dosed reactors, while methanogens community was mainly affected by pH.Goethite inhibited the generation of acetate and increased the butyrate production, which may benefit to keep the pH of the reactors stable.The results revealed the underlying mechanism of goethite to promote performances of anaerobic digestion and confirmed goethite was a potential additive under different pH conditions.

01 Jul 2025·SEPARATION AND PURIFICATION TECHNOLOGY

A novel approach for flotation separation of talc and molybdenite: Scrap steel-molybdenite galvanic corrosion treatment and its mechanism

Author: Ke, Baolin ; Chen, Jianhua ; Lei, Long ; Yao, Lunyu ; Zhu, Haiyang

Molybdenum is an important strategic resource.Talc-type molybdenite is abundant in reserves, but it is difficult to sep. talc and molybdenite efficiently and cleanly because of their similar strong hydrophobicity.In this paper, the effect of galvanic corrosion between scrap steel and molybdenite on flotation behavior of molybdenite was studied under different conditions (different scrap steel materials, slurry water content, galvanic corrosion time and galvanic corrosion ambient temperature).The method for flotation separation of molybdenite and talc by galvanic corrosion of scrap steel-molybdenite was established for the first time.In addition, XPS, SEM, TOF-SIMS, contact Angle test and electrochem. test were used to study the effect of galvanic corrosion of scrap steel-molybdenite on the surface properties of molybdenite and talc.The results show that strong galvanic corrosion between scrap steel and molybdenite can significantly reduce the hydrophobicity of molybdenite, but there is no galvanic corrosion between scrap steel and talc under the same conditions, and scrap steel has no significant effect on the surface hydrophobicity of talc.Therefore, the galvanic corrosion of scrap steel-molybdenite can effectively expand the floatability difference between talc and molybdenite, and strengthen the flotation separation of molybdenite and talc.The flotation test results of artificial mixed ore show that in the case of mineral mixing, the galvanic corrosion of scrap steel-molybdenite still shows a strong inhibition effect on molybdenite flotation, so that 97.04% of molybdenite in the mixed ore is inhibited into the tailings (molybdenite products).The research results expand the new high-value utilization way of scrap steel in sulfide ore flotation, and help to promote the sustainable development of iron and steel industry and sulfide ores industry.In addition, the research results also have reference significance for the use of scrap steel galvanic corrosion to inhibit other sulfide ores such as pyrite and arsenopyrite.

01 Jul 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Synthesis of tannic acid based composite for efficient Congo red removal: Isotherm, kinetics, and thermodynamic studies

Author: Liu, Qiang ; Dong, Yunhui ; Zhang, Xuezhu ; Li, Zhongfang ; Wang, Jigang ; Ma, Shuanhong ; Yang, Qiying ; Niu, Kaiqiang ; Wang, Likai ; Li, Yuntao ; Sun, Shirui ; Ma, Wei ; Liu, Qinze

To remediate the toxic organic dyes in sewage is a challenge task nowadays, because they will pose significant health risks to the ecol. system.This work ingeniously developed a pristine composite α-FeOOH@poly(tannic acid-1,6-hexanediamine) (FeOOH@PTHA) with respect to effectively remove the hazardous Congo red (CR) from simulated solutionMany physicochem. methods were employed to characterize the structure and properties of the resultant adsorbent, such as SEM, EDS, BET, FT-IR, TGA and so on.An elaborate explanation for the influence factors on CR uptake was carried out with batch mode experiments, including initial pH, CR concentration, adsorbent dosage, contact time and temperaturerevealed that the repulsive forces per unit area (RF-PUA) retarded the adsorption progress until it reaching equilibrium state.A favorable monolayer adsorption with the maximum amount (303.03 mg g^-1 at 40 °C) occurred on the homogeneous surface of FeOOH@PTHA, which was ascertained by the Langmuir isotherm model.The well-fitting of pseudo-second-order (P2O) kinetic model and intra-particle diffusion verified the CR chemisorption with a rate-limiting step over FeOOH@PTHA.The thermodn. anal. demonstrated that the removal of CR presented an inherently spontaneous and endothermic character.The hydrogen bonding, π-π stacking and electrostatic attracting between FeOOH@PTHA and CR were responsible for the adsorption motivation.Accordingly, the creditable adsorbent FeOOH@PTHA has potential as a green and efficient option for the remediation of CR-wastewater effluents and solving environmental issues.

News (Medical) associated with Iron sucrose

05 Feb 2025

·www.prnewswire.com

Renibus to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

SOUTHLAKE, Texas, Feb. 5, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference, being held February 11-12, 2025, in a virtual format. Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus, will present on Wednesday, February 12, 2025, at 10:40 am ET. Company management will also meet with investors in one-on-one meetings during the conference. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Fast TrackAcquisition

09 Oct 2024

·www.prnewswire.com

Renibus Therapeutics Announces Oral Presentation on RBT-1 at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

- Renibus is actively enrolling a Phase 3 pivotal trial to reduce the risk of post-operative complications and improve outcomes following cardiac surgery - SOUTHLAKE, Texas, Oct. 9, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced that an oral presentation will be delivered on RBT-1 at the 38th EACTS Annual Meeting, taking place October 9-12, 2024, in Lisbon, Portugal. Charles Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery and Vice Chairman of Quality and Patient Safety, New York-Presbyterian Hospital, Weill Cornell Medicine, will be presenting on behalf of Renibus. RBT-1 is a single-dose, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing non-emergent cardiac and/or valve surgery. Renibus is actively enrolling a Phase 3 pivotal trial of RBT-1 to reduce the risk of post-operative complications and improve outcomes following cardiac surgery. RBT-1 has received Breakthrough and Fast Track Designations from the US FDA. "We are thrilled that EACTS has recognized RBT-1 with an oral presentation to share our promising results with the global cardiothoracic surgery community," stated Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus. "Enrollment in the RBT-1 Phase 3 PROTECT study is ahead of schedule, and we remain on track to report top-line data in the second quarter of 2025." "RBT-1 has shown great potential in our Phase 2, multi-center, randomized, double-blind, placebo-controlled study," said Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine. "I am excited to present new data from a post-hoc analysis, which included all patients regardless of surgery delay, showing that the improvement in clinical outcomes in response to RBT-1 treatment was maintained." Details of the oral presentation at EACTS Annual Meeting: Title: Effect of RBT-1 on Clinical Outcomes the Safety Population of a Phase 2 Study in Cardiac Surgery Date and Time: Friday, October 11, 2024, 9:15 am Presenting Author: Charles Mack, MD Authors: C. Mack (New York, USA), M. Jessen (Dallas, USA), A. Shaw (Cleveland, USA), S. Ruiz (Southlake, USA), C. Wang (Piscataway, USA), S. Snapinn (Seattle, USA), B. Singh (Southlake, USA), A. Lamy (Ontario, Canada) About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory and antioxidant pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery. Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Phase 3Fast TrackBreakthrough Therapy

03 Oct 2024

·www.renibus.com

Renibus Therapeutics Presents Two Posters on RBT-1 , a First-in-Class Preconditioning Agent, at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024 Meeting

Southlake, Texas, October 3, 2024, (PR NEWSWIRE) – Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced poster presentations of promising data results on its first-in-class Phase 3 program, RBT-1, at the AMCP Nexus 2024 Meeting, taking place October 14-17, 2024 in Las Vegas, NV. RBT-1 is a single dose preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. RBT-1 is actively enrolling in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. RBT-1 has received Breakthrough and Fast Track Designations from the U.S. FDA. “Presenting at AMCP Nexus 2024 enables Renibus to share our promising RBT-1 results with the cardiothoracic and managed care communities,” stated Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus. “From the completed Phase 2 clinical trial, RBT-1 demonstrated the potential to reduce post-operative complications for patients and significantly lower healthcare costs in cardiac surgery patients, including those undergoing CABG and valve procedures. The data showed cost reductions of up to 30% and fewer complications, such as prolonged ICU stay, new-onset atrial fibrillation and 30 day readmissions. We are excited by these results and will continue to advance RBT-1 through the ongoing Phase 3 PROTECT study, with top-line data expected in the second quarter of 2025.” Details of the poster presentations at AMCP Nexus 2024: Title: Impact of RBT-1 on post-operative complications rates and costs for cardiac surgery Abstract ID: 1855045 Date and Time: Wednesday, October 16, from 11:30am-2:30pm Authors: Frans van Wagenberg, MS, MD, Lynn Cherry, PhD, Bhupinder Singh, MD, Stacey Ruiz, PhD, Raf Magar, MBA Title: Impact of RBT-1 a novel treatment to reduce post-operative complication rates and costs for coronary artery bypass graft (CABG) surgery Abstract ID: 1855213 Date and Time: Wednesday, October 16, from 11:30am-2:30pm Authors: Frans van Wagenberg, MS, MD, Lynn Cherry, PhD, Bhupinder Singh, MD, Stacey Ruiz, PhD, Raf Magar, MBA About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory andantioxidant pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery. Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients’ lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus’ first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company’s website at www.Renibus.com and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point amy@juniper-point.com 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus jdonadio@renibus.com

Phase 3Phase 2Fast TrackClinical ResultBreakthrough Therapy

100 Deals associated with Iron sucrose

External Link

KEGG	Wiki	ATC	Drug Bank
D04616	Iron sucrose	B03AB02	DB09146

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Kidney Failure, Chronic	Canada	Vifor Fresenius Medical Care Renal Pharma Ltd.	05 Jan 2018
Hyperphosphatemia	Japan	Kissei Pharmaceutical Co., Ltd.	28 Sep 2015
Chronic Kidney Diseases	United States	American Regent, Inc.	06 Nov 2000
Iron deficiency	United States	Sanofi-Aventis U.S. LLC	25 Apr 1957
Anemia, Iron-Deficiency	Switzerland	Vifor Pharma AG	02 Jun 1949

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 3	-	American Regent, Inc.	01 Feb 2003
Anemia	Phase 3	-	American Regent, Inc.	01 Jul 2002
Inflammatory Bowel Diseases	Phase 2	United States	American Regent, Inc.	01 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04485039 (CTgov)	Phase 4	Smallpox	44	Tecovirimat (TPOXX: Oral Antiviral)	xamnakkgfh(yfspnwwcnk) = orlzttdwrj lxonhcqpsf (muphmajtre, 39.6) View more	-	09 Oct 2024
				Tecovirimat+sevelamer carbonate oral tablet (TPOXX: Oral Antiviral and Sevelamer Carbonate)	fbiopkoicj(ciqkmtvbui) = cizfbusthn wrozgicrcv (jiaxnrutcy, mxwzciqdem - lqhwnyrkco) View more
SOHO2024	Not Applicable	Hypophosphatemia	-	Ferric hydroxide-sucrose	abripwjkfi(jvarhnsuwp) = tljztnaaba mukkcmwhlc (xyaccqwqpl )	-	04 Sep 2024
SOHO2023	Not Applicable	-	-	Ferric Carboxymaltose (FCM)	gbckttzora(tuiquvynay): risk ratio = 0.97 (95% CI, 0.62 - 1.51), P-Value = 0.86 View more	-	01 Sep 2023
				Iron Sucrose (IS)
DaVita Biorepository (ASN2022)	Not Applicable	iron sucrose	950	Iron Sucrose administration	esuzxztbff(yuzvhoosbw) = jqciamexjd rivejexbsw (uqacwvjnzj )	Positive	05 Nov 2022
				No Iron Sucrose administration	-
ASN2022	Not Applicable	sP \| sCa \| iPTH	100	Sucroferric oxyhydroxide	dswmymhfeq(asjtvfmomh) = nifbijgjdv nfgwfjaexn (wxyqolumqv )	Positive	03 Nov 2022
NCT04046263 (CTgov)	Phase 4	Hyperphosphatemia \| Peritoneal dialysis complication \| Hypoalbuminemia	17	Sucroferric Oxyhydroxide Chewable Tablet	visqxnzajx(fmszhbaglt) = rmlpryicos akmcmsigtp (hcgpaothfv, 1.76) View more	-	31 Aug 2022
ERA2022	Not Applicable	Chronic Kidney Diseases skeletal plasma clearance of tracer (K i ) \| bone volume/tissue volume (BV/TV)	-	Sucroferric oxyhydroxide	plwddchjqe(quamabrvvn) = BV/TV (volume) was significantly lower after SO treatment than after CC treatment tskntsjelh (qsvaorftwk )	-	03 May 2022
				Calcium carbonate
MO809 (ERA2022)	Not Applicable	Hyperphosphatemia	92	Sucroferric Oxyhydroxide	hdvwpxlcbu(azianrqifk) = The drug was well tolerated gczhtvnudt (ryhcwsncxv ) View more	Positive	03 May 2022
ERA2022	Not Applicable	Bone Diseases FGF23 \| soluble Klotho \| c-reactive protein (CRP) ... View more	50	Sucroferric oxyhydroxide	hjpvnnxhgx(ieslisuqcu) = jgkbaprzzu dvwiwbqgmk (uvehabudfg ) View more	Positive	03 May 2022
				Sevelamer	mdvkcpudpz(sukcwebjsu) = redmnkkwyt vppadzxpsc (fcgfqeejmk )
ASN2021	Not Applicable	Peritoneal Diseases	260	Sucroferric Oxyhydroxide (SO)	fatknfaxzz(rgbwtjizbk) = 153% from BL to Q4 ruosxvdrnj (dyllaazhsj ) View more	Positive	27 Oct 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Iron sucrose

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation